Mechanistically, p300-mediated acetylation of C/EBPβ leads to enhanced C/EBPβ transactivation activity on the Arg1 promoter subsequently enhancing Arg1 expression, and pharmacological inhibition of p300 led to reduced MDSC immunosuppressive activity and tumour burden in vivo. The gene discussed is CEBPB; the disease is neoplasm.